In this article, we will be taking a look at the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.
Small-cap stocks are drawing renewed investor attention in 2026 as capital rotates away from years of concentration in mega-cap names. In its Investment Outlook 2026, Goldman Sachs Asset Management said, “Further down the market capitalization spectrum, in the small and mid-cap space, we see potential opportunities among enablers, so-called ‘picks and shovels’ of the AI boom,” signaling that structural AI exposure may increasingly sit outside the largest companies, particularly among ecosystem suppliers.
The firm also emphasized the rate backdrop, stating, “Easing cycles also represent a potential tailwind for rate-sensitive asset classes, like small-cap stocks.” It added, “We also believe small caps in the US and internationally offer compelling opportunities driven by anticipated rate cuts and accelerating earnings,” underscoring that the opportunity is not just valuation-driven but tied to earnings momentum and macro relief converging simultaneously.
On February 19, Ben Snider, Goldman Sachs chief U.S. equity strategist, told CNBC’s “Money Movers” that economic data and fiscal Q4 earnings have been solid, but AI uncertainty has weighed on large parts of the S&P 500. Despite broad market strength, the index is roughly flat year to date, reflecting a shift in the AI narrative from pure optimism to a balance between optimism and disruption.
Snider noted that while tech’s heavy weighting has powered the index in recent years, it is now acting as a drag. The equal-weight S&P 500 is up about 5% to 6%, with roughly 350 of 500 stocks positive year to date, indicating underlying breadth even as large-cap tech becomes a headwind in aggregate.
With that said, let’s now look at the most promising stocks.
Our Methodology
For our methodology, we used screeners to identify stocks with small market caps and an average upside potential of at least 20% and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Here is our list of the 12 most promising small-cap stocks according to Wall Street analysts.
12. CeriBell, Inc. (NASDAQ:CBLL)
CeriBell, Inc. (NASDAQ:CBLL) secures the twelfth place on our list of most promising stocks.
TheFly reported on February 25 that Canaccord reduced its price target for CBLL from $30 to $28 and maintained a Buy rating on the stock. The firm pointed to a strong fourth-quarter earnings beat for the company and noted that management issued cautious guidance despite several upcoming growth drivers.
CeriBell, Inc. (NASDAQ:CBLL) presented results for the fourth quarter and the entire year of 2025 earlier on February 24. The company reported its fourth-quarter sales of $24.8 million, which is up 34% from the previous year. The company said that this growth was fueled by an increase in both new and existing accounts. Subscription sales rose 37% to $6.0 million, while product revenue increased 33% to $18.8 million. The quarter ended with a gross profit of $21.6 million and a gross margin of 87%. At $0.36 per share, the corporation reported a net loss of $13.5 million.
The company’s total income for the year was $89.1 million, up 36% from 2024. This amount included $21.7 million from subscriptions and $67.3 million from products. 88% was the full-year gross margin. With 647 active accounts and $159.3 million in cash, cash equivalents, and marketable securities at the end of 2025, CeriBell, Inc. (NASDAQ:CBLL). A number of FDA clearances were also obtained by the company, which anticipates $111 million to $115 million in sales in 2026.
CeriBell, Inc. (NASDAQ:CBLL) is a medical technology company focused on rapid EEG solutions for neurological care. Its portable brain-monitoring systems use AI-powered analytics to help hospitals quickly detect seizures and improve timely diagnosis and treatment in critical care settings.
11. HealthStream, Inc. (NASDAQ:HSTM)
HealthStream, Inc. (NASDAQ:HSTM) is next on our list of most promising stocks.
TheFly reported on February 25 that Canaccord reduced its price target for HSTM from $25 to $21 and maintained a Hold rating. According to the firm, despite mounting investor fears about AI impacting SaaS firms, the company’s fourth-quarter 2025 performance was excellent. Management discussed these issues and made the case that HSTM is in a better position than many other software businesses to handle the pressures posed by AI during the results call.
On February 23, HealthStream, Inc. (NASDAQ:HSTM) announced its results for the fourth quarter and the entire year 2025. According to the company, its Q4 revenue hit a record $79.7 million, up 7.4% over the previous year. According to the report, operational income and net income, which came to $2.4 million and $2.5 million, respectively, were impacted by a $3.8 million stock-based compensation charge associated with a CEO share contribution. Non-GAAP operating income surged 31.7% to $6.2 million, and non-GAAP EPS rose to $0.18 once this effect was eliminated. Adjusted EBITDA rose by 16.4% to $18.8 million.
In addition, for the full year, the corporation reported that its revenue reached $304.1 million, which is up 4.3%, while adjusted EBITDA grew 7.5% to $71.8 million. The company also completed two acquisitions, repurchased $10 million in shares, and increased its quarterly dividend to $0.035 per share.
HealthStream, Inc. (NASDAQ:HSTM) is a healthcare workforce solutions company providing training, credentialing, and compliance software for hospitals and healthcare organizations. Its cloud-based platforms help improve staff competency, regulatory adherence, and overall patient care quality.
